Malignancy and myositis: Novel autoantibodies and new insights

Current Opinion in Rheumatology

Volumn 22, Issue 6, 2010, Pages 627-632

  Selva O'Callaghan, Albert ^a   Trallero Araguás, Ernesto ^a   Grau Junyent, Josep M ^b   Labrador Horrillo, Moisés ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

antip155 140; cancer associated myositis; dermatomyositis; PET computed tomography; screening

Indexed keywords

AUTOANTIBODY; NERVE CELL ADHESION MOLECULE; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION INTERMEDIARY FACTOR 1 GAMMA; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; CANCER DIAGNOSIS; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; DERMATOMYOSITIS; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; IMMUNOPATHOLOGY; MYOSITIS; NEOPLASM; PARANEOPLASTIC SYNDROME; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

AUTOANTIBODIES; HUMANS; MYOSITIS; NEOPLASMS, UNKNOWN PRIMARY; PARANEOPLASTIC SYNDROMES;

EID: 77958068352     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32833f1075     Document Type: Review

References (40)

1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362:971-982.
2. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 2002; 28:723-741.
3. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. Ann Intern Med 2001; 134:1087-1095.
4. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis: a population-based study. N Engl J Med 1992; 326:363-367.
5. Huang YL, Chen YJ, Lin MW, et al. Malignancies associated with dermato-myositis and polymyositis in Taiwan: a nationwide population-based study. Br J Dermatol 2009; 161:854-860.
6. Antiochos BB, Brown LA, Li Z, et al. Malignancy is associated with derma-tomyositis but not polymyositis in Northern New England, USA. J Rheumatol 2009; 36:2704-2710.
7. Madan V, Chinoy H, Griffiths CEM, Cooper RG. Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol 2009; 34:451-455.
8. Selva-O'Callaghan A, Mijares-Boeckh-Behrens T, Solans-Laque R, et al. The neural network as a predictor of cancer in patients with inflammatory myopathies. Arthritis Rheum 2002; 46:2547-2548.
9. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008; 35:438-444.
10. Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001; 144:825-831.
11. Selva-O'Callaghan A, Fonollosa-Pla V, Trallero-Araguas E, et al. Nailfold capillary microscopy in adults with inflammatory myopathy. Semin Arthritis Rheum 2010; 39:398-404.
12. Rozelle A, Trieu S, Chung L. Malignancy in the setting of the antisynthetase syndrome. J Clin Rheumatol 2008; 14:285-288.
13. Watkins J, Farzaneh-Far R, Tahir H, et al. Jo-1 syndrome with associated poorly differentiated adenocarcinoma. Rheumatology 2004; 43:389-390.
14. Legault D, McDermott J, Crous-Tsanaclis AM, Boire G. Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J Rheumatol 2008;35:169-171.
15. Fardet L, Dupuy A, Gain M, et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009; 88:91-97.
16. Fardet L, Rybojad M, Gain M, et al. Incidence, risk factors, and severity of herpesvirus infections in a cohort of 121 patients with primary dermatomyo sitis and dermatomyositis associated with a malignant neoplasm. Arch Der matol 2009; 145:889-893.
17. Seelig HP, Moosbrugger I, Ehrfeld H, et al. The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum 1995; 38:1389-1399.
18. Zhang Y, LeRoy G, Seelig H-P, et al. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998; 95:279-289.
19. Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009; 80:1060-1068.
20. Zampieri S, Valente M, Adami N, et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev 2010; 9:449-453.
21. Jensen M, Berthold F. Targeting the neural cell adhesion molecule in cancer. Cancer Lett 2007; 258:9-21.
22. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201:591-601.
23. Sparsa A, Liozon E, Herrmann F, et al. Routine versus extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 2002; 138:885-890.
24. Madan V, Chinoy H, Griffiths CEM, Cooper RG. Defining cancer risk in dermatomyositis. Part II: assessing diagnostic usefulness of myositis serology. Clin Exp Dermatol 2009; 34:561-565.
25. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54:3682-3689.
26. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47:324-328.
27. Targoff IN, Trieu EP, Levy-Neto M, et al. Autoantibodies to transcriptional intermediary factor-1 gamma (TIF-17) in dermatomyositis [abstract]. Arthritis Rheum 2006; 54:S518.
28. Venturini L, You J,Stadler M, etal. TIF1 7, a novel member of the transcriptional intermediary factor 1 family. Oncogene 1999; 18:1209-1217.
29. Vincent DF, Yan K-P, Treilleux I, et al. Inactivation of TIF17 cooperates with KrasG12D to induce cystic tumors of the pancreas. PLoS Genet 2009; 5:e1000575.
30. Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46:25-28.
31. Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007; 66:1345-1359.
32. Fujikawa K, Kawakami A, Kaji K, et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti155/140-kDa polypep ides, anti140-kD polypeptides, and antiaminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scan J Rheumatol 2009; 38:263-267.
33. Trallero-Araguas E, Labrador-Horrillo M, Selva-O'Callaghan A, etal. Cancer-associated myositis and antip155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 2010; 89:47-52.
34. McKeon A, Apiwattanakul M, Lachance DH, et al. Positron emission tomography-computed tomography in paraneoplastic neurological disorders. Sys tematic analysis and review. Arch Neurol 2010; 67:322-329.
35. Kim HS, Kim CH, ParkYH, Kim WU. 18Fluorinefluorodeoxyglucose-positron emission tomography/computed tomography in dermatomyositis. Joint Bone Spine 2008; 75:506-512.
36. Liau N, Ooi C, Reid C, et al. F-18 FDG PET/CT detection of mediastinal malignancy in a patient with dermatomyositis. Clin Nucl Med 2007; 32:304-305.
37. Munoz MA, Conejo-Mir JS, Congregado-Loscertales M, et al. The utility of positron emission tomography to find an occult neoplasm in a patient with dermatomyositis. J Eur Acad Dermatol Venereol 2007; 21:1418-1419.
38. Selva-O'Callaghan A, Grau JM, Gamez-Cenzano C, et al. Conventional cancer screening versus positron emission tomography/computed tomogra phy in dermatomyositis/polymyositis. Am J Med 2010; 123:558-562.
39. Lei W, LuoY, Yan K, et al. Abnormal methylation in CD4+T cells from patients with systemic lupus erythematosus, systemic esclerosis, and dermatomyosi tis. Scand J Rheumatol 2009; 38:369-374.
40. Brooks WH, Le Dantec C, Pers JO, et al. Epigenetics and autoimmunity. J Autoimmun 2010; 34:207-219.